0 272

Cited 10 times in

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.

Authors
 Cheol Kwak  ;  Tony Tong Lin Wu  ;  Hyun Moo Lee  ;  Hsi Chin Wu  ;  Sung Joon Hong  ;  Yen Chuan Ou  ;  Seok Soo Byun  ;  Hyou Young Rhim  ;  Thian Kheoh  ;  Ying Wan  ;  Howard Yeh  ;  Margaret K Yu  ;  Choung Soo Kim 
Citation
 INTERNATIONAL JOURNAL OF UROLOGY, Vol.21(12) : 1239-1244, 2014 
Journal Title
INTERNATIONAL JOURNAL OF UROLOGY
ISSN
 0919-8172 
Issue Date
2014
MeSH
Aged ; Androgens/metabolism* ; Androstenes/administration & dosage* ; Antineoplastic Agents/administration & dosage ; Disease Progression ; Drug Therapy, Combination ; Glucocorticoids/administration & dosage ; Humans ; Incidence ; Male ; Orchiectomy* ; Prednisolone/administration & dosage* ; Prostatic Neoplasms, Castration-Resistant/drug therapy* ; Prostatic Neoplasms, Castration-Resistant/epidemiology ; Prostatic Neoplasms, Castration-Resistant/secondary ; Republic of Korea/epidemiology ; Survival Rate/trends ; Taiwan/epidemiology ; Taxoids/therapeutic use* ; Treatment Failure
Keywords
abiraterone acetate ; docetaxel ; metastatic castration-resistant prostate cancer ; prednisolone ; prostate-specific antigen
Abstract
OBJECTIVES: To evaluate the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. METHODS: In this single-arm study, 82 metastatic castration-resistant prostate cancer patients who failed docetaxel-based chemotherapy were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate-specific antigen decline ≥ 50% were considered as responding. RESULTS: A total of 35 patients (43%) achieved prostate-specific antigen response (95% confidence interval 32-54). The median time to prostate-specific antigen progression was 4.7 months (95% confidence interval 3.7-8.3); the median overall survival was 11.8 months. Two (4%) of 50 patients with measurable disease achieved partial response. The median testosterone concentration was in the castration range (1.21 nmol/L) throughout the treatment period. Median dehydroepiandrosterone sulfate decreased from 0.725 μmol/L (baseline) to 0.080 μmol/L (cycle 4). The most common adverse event was bone pain (20%); grade 3/4 adverse event of special interest were hypokalemia (7%), fluid retention and liver function abnormalities (5% each), hypertension (2%), and cardiac disorders (1%). CONCLUSIONS: A combination of abiraterone acetate and prednisolone appears to be a favorable second-line treatment in Taiwanese and Korean patients with advanced metastatic castration-resistant prostate cancer after failed docetaxel-based chemotherapy.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/iju.12589/abstract
DOI
10.1111/iju.12589
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Hong, Sung Joon(홍성준) ORCID logo https://orcid.org/0000-0001-9869-065X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138566
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links